Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.
Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
Jeremie Trochu, CEO of the Ardena Group, is proposed as a new member of the board of directors of Nanologica AB. The proposal has been presented by Nanologica’s main owner Flerie Invest AB in connection with Nanologica’s acquisition of Ardena Södertälje AB. The proposal will be resolved at the Extraordinary General Meeting on March 4.
The shareholders of Nanologica AB (publ), org.nr 556664-5023 (the “Company“) are hereby invited to attend the Extraordinary General Meeting to be held on Wednesday, March 4, 2026, at 10.00 a.m. CET at Advokatfirman Lindahl’s premises, at Smålandsgatan 16, Stockholm. Read more: Notice of Extraordinary General Meeting
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES IN ADDITION TO THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED,
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
CEO Andreas Bhagwani presents at Redeye Theme Event Tools and Supplies in Life Science September, 2025.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
